TriSalus Life Sciences Inc

TriSalus Life Sciences Inc has a negative net equity of -$33.86 million, indicating a significant financial leverage position, with total liabilities exceeding total assets by $33.86 million. The company's liquidity position is characterized by a current ratio of 2.8, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents of $20.44 million are insufficient to cover its long-term debt of $33.13 million, indicating a potential liquidity risk. The company's profitability is currently negative, with a net loss of $39.23 million and an operating loss of $26.95 million. The return on equity (ROE) is 1.16%, which is significantly below the industry median for biotechnology firms, indicating poor capital efficiency. The return on assets (ROA) is -1.11%, further highlighting the company's inability to generate returns from its asset base. TriSalus Life Sciences Inc does not disclose specific revenue segments or geographic exposure in the provided data. However, the company's revenue of $45.15 million is likely concentrated in a few therapeutic areas or geographic regions, as is common in the biotechnology industry. The lack of detailed segment data limits the ability to assess diversification risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The operating cash flow of -$18.01 million and free cash flow of -$69.98 million indicate a significant cash outflow, which could hinder the company's ability to fund operations and growth initiatives without external financing. The risk assessment for TriSalus Life Sciences Inc highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in maintaining liquidity. The dilution risk is low, suggesting that the company is not expected to issue a significant number of new shares in the near term. Recent events and filings for TriSalus Life Sciences Inc include analyst estimates with a mean price target of $9.20 and a median price target of $10.00. The mean recommendation from analysts is 2.00, indicating a generally positive outlook, with five buy ratings and no strong buy or hold ratings. These analyst estimates suggest a potential for stock price appreciation, although the company's current financial performance may pose challenges to achieving these targets.